SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corp. (AMEX: INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced today it has granted VGX Pharmaceuticals a worldwide non-exclusive license to its DNA delivery technology for intratumoral delivery of a proprietary gene to control the growth of melanoma and other cancers. Under the terms of the agreement, Inovio will receive from VGX an upfront license fee and payments based on successful completion of clinical and regulatory milestones. Inovio will exclusively supply VGX with electroporation devices for the therapy included in the license agreement and will receive royalties on the sale of products covered by the license.
